Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

5.640 +0.240 (+4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Where Amylyx Pharma Stands With Analysts
Analysts have provided the following ratings for Amylyx Pharma (NASDAQ:AMLX) within the last quarter: 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
4 Analysts Have This to Say About Amylyx Pharma
Analysts have provided the following ratings for Amylyx Pharma (NASDAQ:AMLX) within the last quarter: 
Via Benzinga
After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 70% Today?
Amylyx Pharmaceuticals (AMLX) stock is rocketing higher on Thursday following an update from the FDA on its ALS treatment. 
Via InvestorPlace
FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate
Via Benzinga
The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff
The FDA's advisors will meet Wednesday to discuss the experimental ALS treatment. 
Via Investor's Business Daily
Bounce In Futures Fizzles As Dollar Surge Returns
In premarket trading, Nike shares fall 10% after the sportswear giant cut its margin outlook for the year while reporting surging inventory, fueling worries over consumers’ ability to spend as... 
Via Talk Markets
Why Is IONQ Stock Up 8% Today?
IonQ (IONQ) stock is climbing higher on Friday after the company announced it secured a $13.4 million contract with the AFRL. 
Via InvestorPlace
AMLX Stock Alert: Amylyx Pharma Gains on Huge FDA Win
Shares of Amylyx Pharma are popping today on news that the FDA has greenlit its treatment against the deadly disease ALS. 
Via InvestorPlace
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) rose 42% to $3.21 in pre-market trading after dipping 26% on Thursday. SAI.TECH recently announced the launch of new liquid cooling Bitcoin mining... 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle
The drug has faced two advisory committees and a delayed review date. 
Via Investor's Business Daily
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
From Amylyx Pharmaceuticals
Via Business Wire
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
US Stocks Flat, Crude Oil Rises 2%
U.S. stocks traded almost flat in volatile trading on Thursday following the release of jobless claims data. 
Via Benzinga
US Stocks Turn Higher, Nasdaq Jumps 100 Points
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. 
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details! 
Via InvestorPlace
Dow Drops 100 Points; US Jobless Claims Fall Further Last Week
U.S. stocks traded mostly lower this morning, with the Dow Jones dropping 100 points on Thursday. 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.